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The most common chromosomal translocation in
liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-
CHOP fusion gene. We previously developed a mouse
model of liposarcoma by expressing FUS-CHOP in
murine mesenchymal stem cells. In order to understand
how FUS-CHOP can initiate liposarcoma, we have now
generated transgenic mice expressing altered forms of
the FUS-CHOP protein. Transgenic mice expressing
high levels of CHOP, which lacks the FUS domain, do
not develop any tumor despite its tumorigenicity in vitro
and widespread activity of the EF1a promoter. These
animals consistently show the accumulation of a
glycoprotein material within the terminally dierentiated
adipocytes, a characteristic figure of liposarcomas
associated with FUS-CHOP. On the contrary, trans-
genic mice expressing the altered form of FUS-CHOP
created by the in frame fusion of the FUS domain to the
carboxy end of CHOP (CHOP-FUS) developed lipo-
sarcomas. No tumors of other tissues were found in these
transgenic mice despite widespread activity of the EF1a
promoter. The characteristics of the liposarcomas arising
in the CHOP-FUS mice were very similar to those
previously observed in our FUS-CHOP transgenic mice
indicating that the FUS domain is required not only for
transformation but also influences the phenotype of the
tumor cells. These results provide evidence that the FUS
domain of FUS-CHOP plays a specific and critical role
in the pathogenesis of liposarcoma. Oncogene (2000) 19,
6015 – 6022.
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Introduction
Liposarcoma is the most common soft tissue malig-
nancy in adults accounting for at least 20% of all
sarcomas in this age group (Mack, 1995). Multiple
histologic subtypes of liposarcoma are recognized
including well dierentiated, dedierentiated, myxoid,
round cell, and pleomorphic. The histologic group is
predictive of both the clinical course of the disease and
the ultimate prognosis (Chang et al., 1989). The
myxoid/round cell liposarcomas exhibited the charac-
teristic t(12;16)(q13;p11) translocation (Knight et al.,
1995). The molecular characterization of this transloca-
tion revealed a fusion between the CHOP gene and a
gene called TLS/FUS (Crozat et al., 1993; Rabbitts et
al., 1993), resulting in the RNA-binding domain of
TLS/FUS being replaced by the basic leucine zipper
domain of CHOP, which confers the ability to form
protein dimers (Ron and Habener, 1992; Crozat et al.,
1993). The TLS/FUS gene has also been shown to fuse
with the gene for Ets-like protein ERG as a result of
the translocation t(16;21)(p11;q22) in some patients
with acute nonlymphoblastic leukemia (Shimizu et al.,
1993; Ichikawa et al., 1994; Panagopoulos et al., 1994,
1995). The portion of TLS/FUS that is present in the
TLS/FUS-CHOP and FUS-ERG fusion proteins is
similar and this part has been shown to be an
autonomous transcriptional activation domain (Prasad
et al., 1994; Sa´nchez-Garcı´a and Rabbits, 1994;
Zinszner et al., 1994). In the FUS-CHOP fusion,
transcriptional activation is therefore specifically con-
ferred on the chimeric protein by the FUS segment
after the translocation event (Sa´nchez-Garcı´a and
Rabbitts, 1994). In vitro the transforming eects of
FUS-CHOP have been demonstrated in fibroblasts
(Pe´rez-Losada et al., 2000), but curiously not in 3T3-
L1 cells under conditions expected to yield oncogenic
eects (Zinszner et al., 1994), suggesting that the
function of FUS-CHOP is influenced by the cell
environment in vitro. In transgenic mice in which
FUS-CHOP is ubiquitously expressed, we have shown
that the overexpression of FUS-CHOP results in most
of the symptoms of human liposarcomas, identifying
the FUS-CHOP as the main mechanism in human
liposarcoma. Whereas interference with the normal
process of dierentiation may contribute to the
oncogenic potential of FUS-CHOP fusion protein, it
is a property that they share with the nontransforming
germline CHOP gene product (Zinszner et al., 1994;
Batchvarova et al., 1995). CHOP expression is tightly
regulated. Under normal conditions the gene is
repressed, and CHOP mRNA and protein are absent
from cells (Fornace et al., 1989; Price and Calderwood,
1992; Carlson et al., 1993; Wang et al., 1996). In
contrast with CHOP, FUS is a constitutively activated
gene (Aman et al., 1996). These observations support a
model whereby the FUS-CHOP fusion gene represents
a gain-of-function mutation of CHOP that deregulate
both gene expression and protein activity. In vitro
studies have demonstrated that injection of CHOP-
expressing cells into nude mice produced only small
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tumors with longer latency than that of FUS-CHOP
expressing cells, suggesting that the presence of amino-
terminal sequence from FUS in the chimeric protein is
necessary for realizing its full oncogenic potential
(Zinszner et al., 1994).
In order to examine in vivo how FUS-CHOP can
initiate liposarcoma, we have now generated transgenic
mice expressing two altered forms of the FUS-CHOP
protein. Transgenic mice expressing high levels of
CHOP, which lacks the FUS domain, do not develop
any tumor despite its tumorigenicity in vitro and
widespread activity of the EF1a promoter. These
animals consistently show the accumulation of a
glycoprotein material within the terminally dieren-
tiated adipocytes, a characteristic figure of liposarco-
mas associated with FUS-CHOP. On the contrary,
transgenic mice expressing the altered form of FUS-
CHOP created by the in frame fusion of the FUS
domain to the carboxy end of CHOP (CHOP-FUS)
specifically developed liposarcomas. The characteristics
of the liposarcomas arising in the CHOP-FUS mice
were very similar to those previously observed in our
FUS-CHOP transgenic mice indicating that the func-
tion of FUS-CHOP is independent from the chimeric
junction domain and demonstrating that the FUS
component of the fusion protein acts as an autono-
mous domain which is required not only for
transformation but also influences the phenotype of
the tumor cells. These results provide evidence that the
FUS domain of FUS-CHOP plays a specific and
critical role in the pathogenesis of liposarcoma.
Results
Generation of transgenic mice expressing altered forms of
FUS-CHOP
We previously developed a mouse model of liposarco-
ma by expressing FUS-CHOP from the elongation
factor 1a (EF-1a) promoter in murine mesenchymal
stem cells (Pe´rez-Losada et al., 2000). In order to
understand in vivo how FUS-CHOP can initiate
liposarcoma, we have now generated transgenic mice
expressing two altered forms of the FUS-CHOP
protein. The first truncated protein (CHOP) lacks the
FUS domain (Figure 1a). In vitro this truncated
protein, unable to activate transcription (Prasad et
al., 1994; Sa´nchez-Garcı´a and Rabbitts, 1994; Zinszner
et al., 1994), is able to interfere with the normal
process of adipocyte dierentiation (Zinszner et al.,
1994), a property which shares with FUS-CHOP.
However, CHOP induces growth arrest (Barone et
al., 1994), but CHOP-expressing cells into nude mice
produced tumors with longer latency than that of
FUS-CHOP-expressing cells (Zinszner et al., 1994).
The second altered form of FUS-CHOP was created
by the in frame fusion of the FUS domain to the
carboxy end of CHOP (CHOP-FUS) (Figure 1a). The
reason to make this second altered form is to
investigate the contribution of both the FUS domain
and chimeric junction of FUS-CHOP to the genesis of
liposarcoma in vivo. This artificial CHOP-FUS chi-
meric protein cannot be recognized by specific
antibodies raised against both the amino and the
carboxy ends of the wild-type FUS-CHOP protein,
indicating that the junction generates dierent domains
in CHOP-FUS and FUS-CHOP proteins. As FUS
contributes a strong transcriptional activation domain
to the fusion protein (Prasad et al., 1994; Sa´nchez-
Garcı´a and Rabbitts, 1994; Zinszner et al., 1994),
before producing transgenic animals we validated the
characteristics of our CHOP-FUS cDNA construct on
transcriptional activity. The eects of CHOP-FUS were
similar to FUS-CHOP (data not shown), indicating
that the FUS domain is an autonomous domain which
does not require the junction to the amino end of
CHOP at least for transcriptional activity.
In order to examine the direct consequences of
CHOP and CHOP-FUS expression in vivo we follow
the same strategy than we previously used for FUS-
CHOP (Pe´rez-Losada et al., 2000). Therefore, CHOP
and CHOP-FUS cDNAs were cloned downstream the
EF-1a promoter (EF-CHOP and EF-CHIOP-FUS) to
direct expression to all tissues (Figure 1b) and injected
into C57BL/66CBA fertilized eggs. Three founders
were obtained for EF-CHOP (IS345, IS329, and IS267)
and two founders for EF-CHOP-FUS (IS418, and
IS438) (Table 1). All founder lines for both EF-CHOP
and EF-CHOP-FUS showed germline transmission of
the transgene. Transgene expression was observed in all
lines and tissue expression of the EF-CHOP and EF-
CHOP-FUS transgenes were demonstrated by Western
blot analysis with an 9E10 monoclonal antibody
(Figure 1c). The elongation factor 1a (EF-1a) promoter
successfully drove the expression of FUS-CHOP in
dierent tissues in the mouse (Figure 1c), showing no
preferential expression in fat-tissues and transgenic
expression was detected in both male and female mice.
Normal mouse fat cells treated in parallel did not
exhibit any expression.
EF-CHOP transgenic mice develop normally
Cohorts of transgenic mice were generated to analyse
the eect of the CHOP gene (Table 1). CHOP
transgenic mice developed healthy, were fertile and
none of the CHOP transgenic mice developed
liposarcomas in up to 24 months of observation (Table
1). This result contrasts with our observations in the
FUS-CHOP transgenic mice. In these mice, liposarco-
mas developed in both independently derived founder
lines beginning at 3 months of age, and by 10 months
of age liposarcoma had appeared in all mice of the two
highest expressing FUS-CHOP lines (Pe´rez-Losada et
al., 2000). Although liposarcomas did not develop in
the CHOP transgenic mice, we investigated whether the
CHOP protein altered white adipose tissue (WAT)
development in these mice. The histopathological
analyses of the white adipose depots in CHOP
transgenic mice did not evidence any pathological
change within the terminally dierentiated adipocytes
(Figure 2). On the contrary, CHOP transgenic mice
had a normal architecture of the tissue and we did not
observe any shift in the WAT toward immature in the
CHOP transgenic mice (Figure 2). The histopathologi-
cal examination only showed the accumulation of an
unknown material in the mature adipocytes. This
material was not present in normal WAT neither in
normal BAT (Figure 2). As FUS-CHOP is associated
with myxoid liposarcomas, we used a routine cyto-
chemical technique to provide clues as to composition.
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The Periodic Acid-Schi (PAS) is a specific stain for all
cells containing glycogen. This cytochemical technique
clearly demonstrates the presence of PAS-positive
material within CHOP-adipocytes (Figure 3f – h).
Positive reaction is also present in myxoid liposarco-
mas arising in mice expressing FUS-CHOP (Figure 3e).
Control cells derived from adipose tissues coming from
wild-type mice are PAS-negative (Figure 3a – d).
Although the promoter drove the expression of CHOP
in dierent tissues in the mice (Figure 1c), the
examination of other organs in these CHOP transgenic
mice did not evidence other abnormalities.
The inability of CHOP to generate tumors and
perturb WAT development in vivo contrasts with its
eects in vitro where CHOP shares some properties of
FUS-CHOP protein: the capacity to inhibit adipocyte
dierentiation and generate tumors in nude mice
(Zinszner et al., 1994). These capacities contrast with
the ability of CHOP to induce growth arrest (Barone et
al., 1994) and enhance dierentiation of erythroid cells
(Cui et al., 2000). Thus, our results demonstrate that
some of the in vitro properties of CHOP do not
correlate in vivo with the normal development of
CHOP mice and indicate that the properties conferred
Figure 1 EF-CHOP and CHOP-FUS transgenic mice: transgene construct and expression. (a) Schematic representation of the
FUS-CHOP protein created as a result of the t(12;16)(q13;p11) chromosomal translocation and the altered forms of FUS-CHOP,
CHOP and CHOP-FUS proteins, used in this study. (b) The human CHOP and CHOP-FUS cDNAs containing a tag-sequence for
the human c-Myc (amino acids 408 – 439) at the 3’ end were cloned into the pEF-BOS vector, which contains the EF-1 promoter
sequences and polyadenylation and splice signals from the human G-CSF gene, to give pEF-CHOP and pEF-CHOP-FUS.
Expression of CHOP and CHOP-FUS proteins in transgenic mice was determined by Western blot analysis. (c) Expression of the
transgene was demonstrated in the liver (L), heart (H), kidney (K), and fat (F) of a 2-month-old EF-CHOP (line IS345) and EF-
CHOP-FUS (line IS438) transgenic (TG), respectively. As a negative control we used the fat from a 2-month-old nontransgenic
(NTG) littermate. The location of CHOP and CHOP-FUS is as indicated
Table 1 Incidence and age of tumor-onset in the transgenic mice expressing altered forms of FUS-CHOP protein
Transgenic line Mice autopsied* Mice with tumor (%). Age in months at tumor onset Tumor type
IS345 (EF-CHOP) 125 0 - -
IS 329 (EF-CHOP) 92 0 - -
IS267 (EF-CHOP) 103 0 - -
IS438 (EF-CHOPFUS) 54 54 (100%) 5 – 9 Liposarcoma
IS418 (EF-CHOPFUS) 79 79 (100%) 5 – 8 Liposarcoma
*Number of EF-CHOP mice analysed during their lifespan and EF-CHOPFUS mice studied during or after the period of liposarcoma
development. .Number of EF-CHOPFUS mice that had liposarcoma as determined at autopsy and percentage of tumor incidence
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by FUS to the FUS-CHOP fusion protein are essential
for the genesis of liposarcoma.
CHOP-FUS transgenic mice develop liposarcomas
We next investigated the contribution of the FUS
domain to the genesis of liposarcoma in vivo by the
generation of cohorts of transgenic mice to analyse the
eect of the CHOP-FUS fusion gene (Table 1).
Uniformly, male and female EF-CHOP-FUS transgenic
mice showed the same symptoms beginning as early as
8 weeks of age with increasing signs over time leading
to death in 100% of the mice by 12 months of age
(Table 1). The survival was similar in the two founder
lines. At the time of autopsy, these animals had
developed palpable masses involving the adipose
tissues, which, upon dissection, revealed white adipose
pads 4 – 100-fold normal size). Tumor infiltration of
non-adipose tissues was not usually visible and was
confirmed microscopically. All these animals had visible
masses as early as 8 – 10 weeks. In addition, some
animals not included in the Table 1 never developed
palpable masses but showed microscopic tumors upon
dissection when they were sacrificed at 10 weeks of age.
This examination is consistent with adipose tissue
disease. However, no tumors of other tissues were
found in these EF-CHOP-SUS transgenic mice, despite
widespread activity of the EF-1a promoter.
We next defined the adipose tissue disease generated
in our EF-CHOP-FUS transgenic mice. Detailed
Figure 2 Histologic appearance of the adipose tissues in EF-CHOP transgenic mice. The adipose tissue in EF-CHOP transgenic
mice in the region of the testis (c,d) or intestine (e,f) shows the accumulation of an unknown material within adipocytes compared to
control brown adipose tissue (a) and normal white adipose tissue (b). The original magnification is 610 for (a,b,c,e) and 620 for
(d,f). BAT, brown adipose tissue; WAT, white adipose tissue; t, testis
Figure 3 Histologic appearance of the adipose tissue in EC-CHOP transgenic mice stained with the PAS technique. The PAS is a
specific stain for all cells containing glycogen. This cytochemical technique clearly demonstrates the presence of PAS-positive
material within CHOP-adipocytes (f,g,h). Positive reaction is also present in myxoid liposarcomas arising in mice expressing FUS-
CHOP (e). Control cells derived from adipose tissues coming from wild-type mice are PAS-negative (a – d)
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analysis of the tumor cells in the EF-CHOP-FUS
transgenic mice established the diagnosis as malignant
liposarcomas. Haematoxilin/eosin staining showed that
the tumor cells had an adipoblast morphology (Figure
4). Histologically, all tumors were diuse liposarcomas
composed of medium to large cells with round nuclei
and were very similar to human liposarcomas (see
http://www-medlib.med.utah.edu/WebPath/NEOHTML/
NEOPLO52.html) and liposarcomas generated in FUS-
CHOP transgenic mice (Pe´rez-Losada et al., 2000). The
histopathological analyses of the white adipose depots
in both EF-CHOP-FUS transgenic lines revealed
multiple abnormalities. Some contained only modest
morphological changes consisting primarily of an
increase in nuclear size and number per microscopic
field, but the white adipose tissue (WAT) of the
majority of the mice had a much more hypercellular
appearance and contained scattered cells with enlarged
pleomorphic nuclei. Similarly to FUS-CHOP trans-
genic mice, CHOP-FUS animals with large sarcomas
had relatively small WAT depots. In these white fat
pads the normal architecture of the tissues was largely
or completely disrupted by the extensive proliferation
of white adipocytes. Virtually all of the white
adipocytes in these dysplastic depots had some degree
of cytological atypia such as cellular or nuclear
enlargement and pleomorphism (Figure 4). Nests of
compact anaplastic liposarcoma cells were often
scattered throughout these depots. Similarly to FUS-
CHOP transgenic mice, WAT deposits in these animals
were generally aected at least with abnormal
adipocytes and, in some cases, foci of sarcomas were
clearly discernible. Pathological changes were not
observed in the brown adipose tissue (BAT) of these
transgenic mice. Histopathological examination of the
other organs of these animals showed no other
abnormalities, with the exception of skeletal abnorm-
alities. These skeletal defects include scoliosis and
curvature and lesions extended over the entire spine,
however, the larger lesions were predominantly present
in the thoracic and upper lumbar regions, which were
similar to FUS-CHOP transgenic mice (Pe´rez-Losada
et al., 2000). We did not find a focus of tumor cells in
any of these organs. The tumors were invariably found
in the WAT depots, usually multifocally in any WAT
depot.
To test the malignant nature of cells from the EF-
CHOP-FUS transgenic mice, 16106 cells from lipo-
sarcoma tumors were injected subcutaneously into 40
day-old nude mice. Thirty-two mice injected developed
progressively growing tumors within 4 – 7 weeks of
transplantation. The transplanted cells developed into
the same kind of tumor as defined by histological
analysis. Furthermore, the origin of liposarcoma cells
from donor mice was confirmed by PCR analysis
revealing the presence of the CHOP-FUS gene
product. These data define the tumors generated in
the EF-CHOP-FUS transgenic mice as malignant
liposarcomas. We next examined the expression of
adipocyte-specific genes in order to define the level at
Figure 4 Liposarcoma development and WAT abnormalities in EF-CHOP-FUS transgenic mice. Hematoxylin-eosin stained
section of the adipose tissue from an EF-CHOP-FUS transgenic mouse that developed a liposarcoma in the region of the testis
shows the eacement of the normal fat architecture (b) compared to control mice (a). At high magnification (c), the presence of the
lipoblasts are visible in this liposarcoma which correspond to a high grade myxoid/round cell type. (d) Microscopic appearance of a
liposarcoma arising in the inter-escapular region. Note the lipid droplets in some, but not all, cells as well as the nuclear
pleomorphism. The arrow indicates the presence of vacuolated, lipid filled cells, to determine the cell of origin. This liposarcoma
gave metastasis to dierent regions. The histology confirmed the tumor origin as shown in (e). (f) Retroperitoneum was another
primary site for liposarcomas in the EF-CHOP-FUS transgenic mice. Although the liposarcoma disease in EF-CHOP-FUS
transgenic mice was very similar, the level of adipoblast infiltration in the two dierent EF-CHOP-FUS transgenic lines revealed by
histological analysis was not identical. Similar results were found in multiple sections from EF-CHOP-FUS transgenic and
nontransgenic mice. The original magnification is 610 for (a,b,d,e,f); 620 for (c)
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which the dierentiation is blocked in CHOP-FUS
liposarcomas. Similarly to FUS-CHOP transgenic mice
(Pe´rez-Losada et al., 2000) and despite their block in
dierentiation each liposarcoma examined was found
to express significant levels of PPAR-g RNA, c/EBPb,
d and a and aP2 comparable to that of normal fat and
FUS-CHOP liposarcomas (data not shown). These
results suggest that liposarcomas in CHOP-FUS
transgenic mice have been transformed at a point in
the dierentiation process after induction of PPARg
expression. Moreover, PPARg is not expressed in any
other type of soft tissue sarcoma (Tontonoz et al.,
1997) and can be considered a sensitive marker for
distinguishing liposarcoma from other histologic types
of soft tissue sarcoma. Therefore, EF-CHOP-FUS
transgenic mice reproduce the same phenotype with
which the FUS-CHOP fusion gene is associated both
in human pathology and transgenic mice (Pe´rez-
Losada et al., 2000). These observations demonstrate
that the chimeric junction sequence is not necessary for
the genesis of liposarcoma and two independent
domains within the FUS-CHOP protein are the main
mechanisms by which FUS-CHOP generates liposar-
coma.
Embryonic fibroblasts from CHOP mice differentiate into
adipocytes but adipocyte differentiation is blocked in
embryonic fibroblasts from CHOP-FUS mice
To investigate whether CHOP-FUS protein retains the
same adipocyte inhibition capacity than FUS-CHOP
and the dierence in the results obtained from the
present analysis of CHOP transgenic mice and
previous in vitro culture systems where CHOP
interferes with the normal process of adipocytic
dierentiation (Zinszner et al., 1994; Kuroda et al.,
1997; Adelmant et al., 1998), we prepared primary
embryonic fibroblasts from CHOP and CHOP-FUS
mice and examined their dierentiation properties as
previously described (Pe´rez-Losada et al., 2000). The
embryonic fibroblasts from each line were cultured to
confluent and then treated with the standard dier-
entiation induction medium. As shown in Figure 5,
embryonic fibroblasts from wild-type and CHOP mice
dierentiated into adipocytes and accumulated many
lipid droplets in response to hormonal stimulants. In
contrast, CHOP-FUS embryonic fibroblasts can hardly
dierentiate into adipogenic cells and accumulate very
few lipid droplets, similarly to FUS-CHOP embryonic
fibroblasts (Figure 5). The Oil-Red-O staining demon-
strated clear dierences in adipocyte phenotype (Figure
5) and, similarly to FUS-CHOP MEFs, MEFs from
CHOP-FUS transgenic mice only expressed the earliest
markers of dierentiation (data not shown), which
corresponds to preadipocytes. These results show that
adipocyte dierentiation was blocked in cultured
CHOP-FUS embryonic fibroblasts but not in MEFs
derived from CHOP transgenic mice treated with
adipogenic hormones. Interference with the normal
process of dierentiation contributes to the oncogenic
potential of FUS-CHOP fusion protein (Pe´rez-Losada
et al., 2000) and this capacity is retained by CHOP-
FUS. On the contrary, CHOP is not able to interfere
with this normal process of adipocytic dierentiation,
explaining why CHOP mice do not develop liposarco-
mas.
Concluding remarks
We have demonstrated that directing expression of the
FUS-CHOP fusion protein to immature mouse cells
initiated sarcomas with adipose features (Pe´rez-Losada
et al., 2000). We have now similarly expressed altered
forms of FUS-CHOP. The results show that the
truncated protein CHOP which lacks the FUS
activation domain does not generate any tumors
neither aect the development of WAT in vivo.
Concordant with these data, adipocyte dierentiation
was not blocked in cultured CHOP embryonic
fibroblasts treated with adipogenic hormones. Thus,
these results show that the transcriptional activation by
FUS is indispensable for tumorigenesis. However, the
genesis of liposarcoma could be explained by properties
of FUS-CHOP protein which derived from the
junction sequence. For this purpose we fused the
FUS domain to the carboxy end of CHOP. The
consequent overexpression of CHOP-FUS resulted in
most of the symptoms of human liposarcomas,
including the presence of lipoblasts with round nuclei,
accumulation of intracellular lipid, induction of
adipocyte-specific genes and a concordant block in
the dierentiation program. No tumors of other tissues
were found in these transgenic mice despite widespread
activity of the EF1a promoter, underscoring the
relevance of the relationship between FUS-CHOP
and the cell environment.
Figure 5 Adipogenic dierentiation from primary embryonic
fibroblasts expressing altered forms of FUS-CHOP protein.
Primary embryonic fibroblasts from each transgenic line were
cultured in the presence of standard dierentiation induction
medium (containing 0.5 mM isobutylmethylxantine, 1 mM dexa-
methasone, 5 mg/ml insulin and 10% FBS). After 8 days of
dierentiation, cells were observed by light microscopy with Oil-
Red-O staining. Cells from nontransgenic, FUS-CHOP, CHOP
and CHOP-FUS mice are shown. The original magnification is
620. This experiment was repeated three times using cells
prepared from all transgenic lines and from dierent embryos
and similar results were obtained
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In both EF-CHOP-FUS transgenic lines multiple
palpable adipose tumors synchronously arise. Their
simultaneous occurrence, extensively involving all
adipose areas, is consistent with the diuse, polyclonal
origin of these tumors, similarly to FUS-CHOP
transgenic mice. These data and our previous observa-
tions (Pe´rez-Losada et al., 2000) strongly support that
FUS-CHOP is a single-step action oncogene which
transforms the target cell. In fact, if one considers the
combined eects of FUS-CHOP and CHOP-FUS on
dierentiation and proliferation controls, it seems
reasonable to think that the single chromosome
abnormality that leads to the generation of this protein
may be all that is needed for the liposarcoma target
cells to become transformed (Sa´nchez-Garcı´a, 1997).
The fact that liposarcomas only arise in CHOP-FUS
transgenic but not in CHOP transgenic mice establishes
the FUS domain as a key determinant of human
liposarcomas. Although, in vitro it is possible that
FUS-CHOP and its normal counterpart CHOP inhibit
dierentiation by interfering with the activation of
transcription by C/EBP family members. In vivo,
however, it seems that CHOP is not able to sequester
C/EBPs. Alternatively, FUS-CHOP may modify the C/
EBP response by altering the subset of DNA-binding
sites through which C/EBPs activate transcription.
Further studies to identify the target genes and
proteins that are regulated by FUS-CHOP using our
transgenic mice will produce a clearer picture of the
development defect in liposarcoma. Our results
demonstrate that the order of the two sequences
(FUS and CHOP) is interchangeable, but they do not
clarify whether the relationship between the FUS and
CHOP domains is in cis or in trans. Further studies will
be required to clarify this point.
Materials and methods
The generation and screening of transgenic mice
PCR amplification of the CHOP portion of FUS-CHOP was
done to facilitate cloning by adding restriction enzymes using
primers that hybridize to the 5’ and 3’ ends of the CHOP
cDNA. The artificial CHOP-FUS in frame fusion was created
by PCR (fusion point: 5’...(chop)....CTGCACCAAGCA-
CTCGAGATGGCCTCAAAC...(FUS)....3’). The products
were cloned into the M13mp19 vector, added to 3’ end an
in-frame sequence coding for a MYC-tag recognized for the
9E10 antibody, and sequenced. The cDNA was cloned into a
plasmid, pEF-BOS, containing sequences of the EF1-a
promoter, followed by a polylinker region linked to the
poly(A) adenylation signal from human G-CSF cDNA as
described (Mizushima and Nagata, 1990). Linear DNA
fragments for microinjection were obtained by HindIII
digestion and injected by the INIA Transgenic Facility into
CBA6C57BL/6J fertilized eggs. Transgenic founders were
identified by Southern-blot analysis through detection of the
novel EF-CHOP and EF-CHOP-FUS constructs from
samples of DNA extracted from tails, respectively.
Histological analysis
CHOP-FUS and CHOP transgenic mice were subjected to
standard necropsy. All major organs were closely examined
under the dissecting microscope, and samples of each organ
were processed into paran, sectioned and examined
histologically. Tumor specimens from the CHOP-FUS
transgenic mice were fixed into 10% formalin overnight,
then processed, embedded in paran, and 6 mm sections were
stained with hematoxylin and eosin and photographed. All
tissue samples were taken from homogenous and viable
portions of the resected sample by the pathologist and fixed
within 2 – 5 min of excision. Hematoxylin- and eosin-stained
sections of each soft tissue sarcoma were reviewed by a single
pathologist (T Flores) and classified according to histologic
type and grade. Histological classification was based solely on
morphologic pattern recognition using conventional diagnos-
tic criteria. Adipose tissues from CHOP transgenic mice were
also stained with the Periodic Acid-Schi (PAS) reaction.
Cell transplantation to nude mice
Liposarcoma tumors were dispersed in Dulbecco’s modified
Eagle’s medium containing 5% fetal calf serum by mechan-
ical shearing onto a large mesh grid and injected subcuta-
neously into 40 day-old nude mice. Approximately 106 cells
were injected at each site. Mice were monitored once a week
and were killed for histopathologic studies and collection of
tissues for DNA analyses when moribund.
Preparation of primary embryonic fibroblasts and induction of
adipogenic differentiation
Primary embryonic fibroblasts were harvested from
14.5 d.p.c. embryos. Cells were cultured at 378C in
Dulbeccos-modified Eagle’s medium (DMEM; Boehringer
Ingelheim) supplemented with 10% heat-inactivated FBS
(GIBCO/BRL). Cells were plated to 24-well or 60 mm plastic
dishes and propagated to confluence. Two days later, medium
was replaced with standard dierentiation induction medium
containing 0.5 mM isobutylmethylxantine (Sigma), 1 mM
dexamethasone (Sigma), 5 mg/ml insulin (Sigma) and 10%
FBS (GIBCO/BRL). This medium was removed every other
day. After 8 days, the appearance of cytoplasmic lipid
accumulation was observed by microscopy with Oil-Red-O
staining. The Oil-Red-O staining was performed as follows:
cells were washed with phosphate-buered saline (PBS), and
then stained with 60% filtered Oil-Red-O stock solution
(0.15 g of Oil-Red-O (Sigma) in 50 ml of isopropanol) for
30 min at 378C. Cells were washed first with 60%
isopropanol and then briefly with water and visualized.
Western blot analysis
Single cell suspensions coming from dierent tissue samples
were analysed by immunoblotting procedures as essentially as
described (Castellanos et al., 1997). Lysates were run on a
10% SDS–PAGE gel and transferred to a PVDF membrane.
After blocking, the membrane was probed with c-Myc (9E10)
mouse monoclonal antibody (Santa Cruz), which is specific
for human c-Myc (amino acids 408 – 439). Reactive bands
were detected with an ECL system (Amersham).
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